dobutamine ๐Ÿถ Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
dopaminergic agents dopamine derivatives used as cardiac stimulant/antihypertensives/diuretics 937 34368-04-2

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • dobutamine
  • dobutamine hydrochloride
  • dobutamine HCl
A catecholamine derivative with specificity for BETA-1 ADRENERGIC RECEPTORS. It is commonly used as a cardiotonic agent after CARDIAC SURGERY and during DOBUTAMINE STRESS ECHOCARDIOGRAPHY.
  • Molecular weight: 301.39
  • Formula: C18H23NO3
  • CLOGP: 2.43
  • LIPINSKI: 0
  • HAC: 4
  • HDO: 4
  • TPSA: 72.72
  • ALOGS: -4.34
  • ROTB: 7
  • Status: OFP
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
0.50 g P

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 0.10 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 0.13 ยตM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 0 %
CL (Clearance) 115 mL/min/kg Lombardo F, Berellini G, Obach RS

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
azlogd74 LogD at pH 7.4 0.110 High 1
caco2-efflux Caco-2 efflux ratio (BA/AB) 1.361 High 1
caco2-intrinsic-papp Caco-2 intrinsic apparent permeability 2.046 10^-6 cm/s High 1
dh-clint Dog hepatocyte intrinsic clearance 14.622 uL/min/10^6 cells High 1
dppb Dog plasma protein binding (% unbound) 44.780 % High 1
fcs-ppb Fetal calf serum protein binding (% unbound) 66.560 % High 1
herg hERG pIC50 4.934 pIC50 High 1
hh-clint Human hepatocyte intrinsic clearance 20.277 uL/min/10^6 cells High 1
hlm-clint Human liver microsomal intrinsic clearance 11.041 uL/min/mg protein High 1
hppb Human plasma protein binding (% unbound) 54.880 % High 1
kinase-safety-class ACVR2A,ACVR2B,AKT2,AKT3,ALK,AURKA,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK2,CDK4,CDK5,CDK9,DDR1,DYRK1B,EGFR,EIF2AK3,EPHB4,ERBB2,FLT3,GRK2,GRK3,GSK3B,IGF1R,ITK,JAK1,JAK2,JAK3,KDR,KIT,MAP2K6,MAP3K14,MAP3K21,MAP3K7,MAP4K1,MAPK1,MAPK10,MAPK14,MAPK7,MAPK8,MAPK9,MAPKAPK2,MARK4,MTOR,NTRK2,PDK1,PDK2,PDK4,PDPK1,PIK3CB,PIM2,PLK1,PLK2,PLK3,PLK4,PRKCD,PRKDC,SIK2,SIK3,STK33,SYK,TEK,TGFBR1,TTK,ULK1,ULK2,ZAP70 69
kinase-selectivity-class ACVR2B,ACVRL1,AXL,BRAF,CAMK2B,CAMK2D,CDK4,CDK9,DDR1,DYRK1B,EIF2AK3,EPHB4,GRK2,INSR,JAK2,MAP2K6,MAPK12,MAPK8,PRKCD,SIK2,STK33,SYK,TEK,TGFBR1,ULK1,ULK2 26
mdck-mdr1-efflux MDCK-MDR1 efflux ratio 2.506 High 1
mh-clint Mouse hepatocyte intrinsic clearance 217.270 High 1
mppb Mouse plasma protein binding (% unbound) 60.440 High 1
nih-mdck-mdr1-efflux NIH MDCK-MDR1 efflux ratio 5.117 High 1
pfas-class PFAS structural alert (1 = True, 0 = False) 0
pppb Pig plasma protein binding (% unbound) 69.270 % High 1
rh-clint Rat hepatocyte intrinsic clearance 115.080 uL/min/10^6 cells High 1
rh-fuinc Rat hepatocyte fraction unbound in incubation 81.010 % High 1
rppb Rat plasma protein binding (% unbound) 49.540 % High 1
solubility-dd Solubility at pH 7.4 in DMSO 595.662 uM High 1

Approvals:

DateAgencyCompanyOrphan
July 18, 1978 FDA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Stress cardiomyopathy 216.75 27.25 64 5440 13291 90609652
Drug ineffective 215.25 27.25 333 5171 1383965 89238978
Cardiogenic shock 205.46 27.25 71 5433 24397 90598546
Multiple organ dysfunction syndrome 135.17 27.25 71 5433 68265 90554678
Cardiac failure 83.35 27.25 62 5442 109434 90513509
Drug ineffective for unapproved indication 67.59 27.25 45 5459 66599 90556344
Vasoplegia syndrome 66.03 27.25 18 5486 2796 90620147
Toxic epidermal necrolysis 64.82 27.25 34 5470 32494 90590449
Ventricular fibrillation 56.99 27.25 24 5480 14020 90608923
Pulmonary hypertension 56.31 27.25 34 5470 42489 90580454
Septic shock 51.70 27.25 42 5462 84118 90538825
Pulmonary arterial hypertension 51.11 27.25 27 5477 26160 90596783
Cardiac arrest 49.47 27.25 45 5459 104890 90518053
Renal impairment 49.29 27.25 45 5459 105376 90517567
Ventricular tachycardia 44.08 27.25 24 5480 24684 90598259
Right ventricular failure 43.82 27.25 22 5482 19183 90603760
Ventricular hypokinesia 42.85 27.25 15 5489 5326 90617617
Sepsis 41.80 27.25 53 5451 179761 90443182
Shock 40.67 27.25 24 5480 28754 90594189
Complications of transplanted heart 40.63 27.25 7 5497 121 90622822
Condition aggravated 38.24 27.25 100 5404 595445 90027498
Left ventricle outflow tract obstruction 37.79 27.25 8 5496 424 90622519
Stevens-Johnson syndrome 37.63 27.25 23 5481 29353 90593590
Local anaesthetic systemic toxicity 36.63 27.25 12 5492 3488 90619455
Heparin-induced thrombocytopenia 35.39 27.25 13 5491 5299 90617644
Disseminated mucormycosis 34.28 27.25 8 5496 663 90622280
Respiratory failure 34.22 27.25 39 5465 118379 90504564
Hypoxia 34.01 27.25 31 5473 72368 90550575
Renal failure 32.65 27.25 40 5464 130967 90491976
Heart transplant rejection 32.46 27.25 8 5496 836 90622107
Fatigue 32.24 27.25 15 5489 1154008 89468935
Ureaplasma infection 31.91 27.25 8 5496 897 90622046
Off label use 31.49 27.25 141 5363 1102111 89520832
Haemodynamic instability 31.43 27.25 15 5489 11724 90611219
Disseminated intravascular coagulation 30.53 27.25 18 5486 21520 90601423
Status epilepticus 30.01 27.25 17 5487 18857 90604086
Hypotension 29.97 27.25 63 5441 325334 90297609
Pulmonary oedema 29.97 27.25 27 5477 62053 90560890
Lactic acidosis 28.50 27.25 24 5480 50439 90572504
Torsade de pointes 27.78 27.25 15 5489 15167 90607776
Fungal sepsis 27.69 27.25 8 5496 1533 90621410
Ascites 27.57 27.25 23 5481 47717 90575226

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Appendicolith 620.51 35.93 213 13647 13243 42594232
Appendicitis 549.38 35.93 218 13642 20395 42587080
Multiple organ dysfunction syndrome 455.90 35.93 320 13540 96715 42510760
Stress 440.53 35.93 236 13624 43976 42563499
Ventricular fibrillation 414.38 35.93 200 13660 29923 42577552
Ascites 357.94 35.93 225 13635 56453 42551022
Blood phosphorus increased 338.81 35.93 134 13726 12391 42595084
Abdominal distension 314.33 35.93 227 13633 71508 42535967
Myasthenia gravis 302.77 35.93 133 13727 16004 42591471
Hyperphosphataemia 272.84 35.93 116 13744 12888 42594587
Hyponatraemia 247.10 35.93 228 13632 101234 42506241
Analgesic therapy 238.48 35.93 87 13773 6437 42601038
Sleep disorder therapy 226.49 35.93 85 13775 6809 42600666
Blood uric acid increased 221.97 35.93 106 13754 15441 42592034
Drug therapy 214.47 35.93 80 13780 6300 42601175
Hypophosphataemia 214.44 35.93 114 13746 20831 42586644
Incorrect route of product administration 212.05 35.93 119 13741 24186 42583289
Neuralgia 206.09 35.93 119 13741 25528 42581947
Bacterial infection 204.67 35.93 122 13738 27757 42579718
General physical health deterioration 200.60 35.93 246 13614 151000 42456475
Sepsis 191.77 35.93 277 13583 199057 42408418
Blood cholesterol increased 191.04 35.93 115 13745 26626 42580849
Dry mouth 183.12 35.93 130 13730 39749 42567726
Iron deficiency 175.08 35.93 81 13779 10980 42596495
Antacid therapy 157.99 35.93 59 13801 4658 42602817
Activated partial thromboplastin time prolonged 150.00 35.93 82 13778 15821 42591654
Anticoagulant therapy 149.25 35.93 56 13804 4479 42602996
Constipation 128.17 35.93 206 13654 162085 42445390
Diabetes mellitus 125.07 35.93 124 13736 59963 42547512
Swelling 124.99 35.93 119 13741 54766 42552709
Thrombosis 123.78 35.93 131 13729 68380 42539095
End stage renal disease 122.86 35.93 73 13787 16485 42590990
Intentional product misuse 118.33 35.93 122 13738 61778 42545697
Abdominal pain 115.36 35.93 215 13645 190256 42417219
Chronic obstructive pulmonary disease 112.79 35.93 120 13740 62994 42544481
Ulcer 110.42 35.93 68 13792 16373 42591102
Blood calcium increased 109.64 35.93 54 13806 8400 42599075
Sleep disorder 108.96 35.93 104 13756 47991 42559484
Drug hypersensitivity 103.93 35.93 144 13716 99245 42508230
Congenital hiatus hernia 100.13 35.93 46 13814 6128 42601347
Bronchopulmonary aspergillosis allergic 96.32 35.93 41 13819 4557 42602918
Troponin increased 94.08 35.93 65 13795 18997 42588478
Drug intolerance 92.37 35.93 122 13738 80302 42527173
Condition aggravated 91.20 35.93 236 13624 260518 42346957
Blood test abnormal 90.81 35.93 55 13805 12851 42594624
Gout 88.08 35.93 73 13787 27982 42579493
Somnolence 84.95 35.93 159 13701 140946 42466529
Hyperlipidaemia 82.56 35.93 63 13797 21453 42586022
Aortic stenosis 82.18 35.93 45 13815 8700 42598775
Drug ineffective 76.60 35.93 404 13456 629793 41977682
Total lung capacity decreased 75.32 35.93 32 13828 3538 42603937
Bacteroides infection 71.01 35.93 28 13832 2559 42604916
Pulmonary embolism 70.97 35.93 134 13726 119478 42487997
Diarrhoea 65.92 35.93 34 13826 460815 42146660
Pleuritic pain 62.61 35.93 35 13825 7042 42600433
Vomiting 62.22 35.93 221 13639 289502 42317973
Stress cardiomyopathy 62.22 35.93 26 13834 2759 42604716
Fall 60.66 35.93 4 13856 234516 42372959
Aspiration 55.00 35.93 46 13814 17840 42589635
Lung opacity 54.74 35.93 30 13830 5807 42601668
Fatigue 54.05 35.93 38 13822 435603 42171872
Dizziness 52.46 35.93 9 13851 249245 42358230
Micturition urgency 50.45 35.93 37 13823 11861 42595614
Cardiogenic shock 50.33 35.93 60 13800 35580 42571895
Decreased appetite 47.92 35.93 4 13856 193133 42414342
Platelet distribution width increased 47.88 35.93 11 13849 150 42607325
Off label use 44.97 35.93 357 13503 637978 41969497
Weight decreased 44.88 35.93 7 13853 207941 42399534
Malaise 43.89 35.93 8 13852 212148 42395327
Joint injury 43.59 35.93 37 13823 14639 42592836
Breath sounds abnormal 43.31 35.93 34 13826 12059 42595416
Febrile neutropenia 43.04 35.93 5 13855 185698 42421777
Confusional state 42.90 35.93 3 13857 167594 42439881
Toxic epidermal necrolysis 42.74 35.93 48 13812 26702 42580773
Product use in unapproved indication 39.73 35.93 141 13719 184315 42423160
Pruritus 39.29 35.93 7 13853 188764 42418711
Lower respiratory tract infection 37.55 35.93 56 13804 41150 42566325

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Appendicolith 771.49 32.17 219 18542 14036 110556502
Multiple organ dysfunction syndrome 642.50 32.17 369 18392 151341 110419197
Appendicitis 641.61 32.17 224 18537 28240 110542298
Ventricular fibrillation 556.85 32.17 223 18538 41090 110529448
Ascites 441.87 32.17 244 18517 92564 110477974
Blood phosphorus increased 428.14 32.17 144 18617 16196 110554342
Stress 415.67 32.17 245 18516 105103 110465435
Myasthenia gravis 374.74 32.17 140 18621 21371 110549167
Hyperphosphataemia 342.56 32.17 122 18639 16259 110554279
Analgesic therapy 314.64 32.17 94 18667 7190 110563348
Sleep disorder therapy 303.69 32.17 92 18669 7379 110563159
Abdominal distension 296.53 32.17 242 18519 174861 110395677
Drug therapy 284.47 32.17 87 18674 7204 110563334
Sepsis 283.82 32.17 312 18449 327034 110243504
Blood uric acid increased 278.79 32.17 113 18648 21416 110549122
Hypophosphataemia 253.12 32.17 120 18641 33062 110537476
Hyponatraemia 251.03 32.17 242 18519 217411 110353127
Drug ineffective 244.92 32.17 683 18078 1519857 109050681
Bacterial infection 238.17 32.17 128 18633 45908 110524630
Stress cardiomyopathy 225.58 32.17 89 18672 15717 110554821
Neuralgia 223.74 32.17 125 18636 48353 110522185
Antacid therapy 212.07 32.17 65 18696 5419 110565119
Cardiogenic shock 206.82 32.17 126 18635 57212 110513326
Iron deficiency 205.47 32.17 87 18674 18389 110552149
Activated partial thromboplastin time prolonged 202.13 32.17 91 18670 22277 110548261
Anticoagulant therapy 200.78 32.17 62 18699 5299 110565239
Incorrect route of product administration 193.98 32.17 126 18635 63935 110506603
End stage renal disease 167.85 32.17 79 18682 21394 110549144
Thrombosis 160.64 32.17 139 18622 108523 110462015
Diabetes mellitus 154.79 32.17 131 18630 99250 110471288
General physical health deterioration 147.70 32.17 261 18500 425034 110145504
Chronic obstructive pulmonary disease 136.36 32.17 127 18634 109031 110461507
Constipation 135.20 32.17 228 18533 357558 110212980
Congenital hiatus hernia 132.26 32.17 47 18714 6212 110564326
Gout 125.81 32.17 78 18683 36488 110534050
Troponin increased 124.50 32.17 72 18689 29694 110540844
Intentional product misuse 124.14 32.17 132 18629 132772 110437766
Blood calcium increased 118.72 32.17 59 18702 17981 110552557
Aortic stenosis 111.24 32.17 51 18710 13008 110557530
Condition aggravated 105.46 32.17 318 18443 734518 109836020
Bronchopulmonary aspergillosis allergic 104.84 32.17 43 18718 8383 110562155
Hyperlipidaemia 104.78 32.17 69 18692 35779 110534759
Ulcer 104.69 32.17 74 18687 43042 110527496
Pulmonary embolism 102.06 32.17 152 18609 214322 110356216
Arthralgia 96.84 32.17 10 18751 779622 109790916
Blood test abnormal 95.92 32.17 60 18701 28494 110542044
Total lung capacity decreased 90.89 32.17 37 18724 7077 110563461
Somnolence 88.55 32.17 171 18590 297278 110273260
Dry mouth 88.45 32.17 137 18624 199811 110370727
Bacteroides infection 85.50 32.17 28 18733 2891 110567647
Abdominal pain 84.06 32.17 233 18528 512756 110057782
Toxic epidermal necrolysis 82.62 32.17 72 18689 56655 110513883
Fatigue 81.89 32.17 53 18708 1215905 109354633
Off label use 74.70 32.17 471 18290 1499714 109070824
Blood cholesterol increased 73.99 32.17 121 18640 184664 110385874
Fall 69.35 32.17 10 18751 603472 109967066
Lung opacity 67.59 32.17 35 18726 11617 110558921
Aspiration 66.34 32.17 49 18712 30484 110540054
Dizziness 64.94 32.17 19 18742 698174 109872364
Ventricular tachycardia 63.98 32.17 59 18702 49950 110520588
Benign prostatic hyperplasia 62.97 32.17 39 18722 18195 110552343
Vasoplegia syndrome 61.74 32.17 26 18735 5413 110565125
Micturition urgency 60.89 32.17 39 18722 19281 110551257
Pleuritic pain 59.51 32.17 36 18725 16104 110554434
Right ventricular failure 59.44 32.17 43 18718 25911 110544627
Diarrhoea 56.82 32.17 66 18695 1139439 109431099
Sleep disorder 55.18 32.17 111 18650 198533 110372005
Platelet distribution width increased 54.94 32.17 11 18750 151 110570387
Confusional state 53.28 32.17 8 18753 468672 110101866
Weight decreased 53.18 32.17 8 18753 468049 110102489
Pain in extremity 51.66 32.17 10 18751 487108 110083430
Heparin-induced thrombocytopenia 51.42 32.17 29 18732 11395 110559143
Malaise 51.26 32.17 25 18736 671794 109898744
Infusion related reaction 49.63 32.17 4 18757 381158 110189380
Pruritus 48.53 32.17 19 18742 581541 109988997
Cardiac failure 47.58 32.17 101 18660 187525 110383013
Nasopharyngitis 46.53 32.17 6 18755 394355 110176183
Abdominal discomfort 46.45 32.17 6 18755 393852 110176686
Decreased appetite 45.98 32.17 12 18749 475834 110094704
Hypersensitivity 45.67 32.17 7 18754 403991 110166547
Respiratory symptom 44.23 32.17 29 18732 14916 110555622
Drug ineffective for unapproved indication 43.39 32.17 69 18692 102769 110467769
Breath sounds abnormal 42.64 32.17 35 18726 25369 110545169
Rash 42.55 32.17 46 18715 820918 109749620
Product use in unapproved indication 41.62 32.17 168 18593 447209 110123329
Complications of transplanted heart 38.36 32.17 10 18751 462 110570076
Drug hypersensitivity 37.92 32.17 165 18596 453925 110116613
Eosinophilic myocarditis 37.86 32.17 14 18747 2071 110568467
Insomnia 36.97 32.17 8 18753 360582 110209956
Cardiovascular disorder 35.39 32.17 30 18731 22730 110547808
Heart transplant rejection 34.61 32.17 13 18748 2008 110568530
Joint injury 34.28 32.17 38 18723 39956 110530582
Low cardiac output syndrome 33.97 32.17 11 18750 1095 110569443
Blood creatinine increased 33.81 32.17 87 18674 182802 110387736
Hepatic enzyme increased 33.14 32.17 7 18754 320885 110249653
Hypernatraemia 32.97 32.17 26 18735 17807 110552731
Shock 32.94 32.17 43 18718 53545 110516993
Weight increased 32.92 32.17 15 18746 419629 110150909
Febrile neutropenia 32.53 32.17 7 18754 316760 110253778
Left ventricle outflow tract obstruction 32.33 32.17 9 18752 534 110570004

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC C01CA07 CARDIOVASCULAR SYSTEM
CARDIAC THERAPY
CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES
Adrenergic and dopaminergic agents
FDA MoA N0000000245 Adrenergic beta-Agonists
FDA EPC N0000175555 beta-Adrenergic Agonist
MeSH PA D000318 Adrenergic beta-Agonists
MeSH PA D002316 Cardiotonic Agents
MeSH PA D002317 Cardiovascular Agents
MeSH PA D013566 Sympathomimetics
MeSH PA D018377 Neurotransmitter Agents
MeSH PA D018663 Adrenergic Agents
MeSH PA D020011 Protective Agents
MeSH PA D058665 Adrenergic beta-1 Receptor Agonists
CHEBI has role CHEBI:35522 ฮฒ-adrenergic agonist
CHEBI has role CHEBI:35524 sympathomimetic agent
CHEBI has role CHEBI:35554 cardiovascular drug
CHEBI has role CHEBI:38147 cardiotonic drug
CHEBI has role CHEBI:63726 neuroprotective agent

Related Drugs by ATC class:

C01CA Adrenergic and dopaminergic agents 25 drugs
amezinium metilsulfatearbutaminecafedrinedimetofrinedopaminedopexaminedroxidopaephedrineepinephrineetilefrinefenoldopamgepefrine show all 25 →

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Cardiogenic shock indication 89138009
Decompensated cardiac failure indication 195111005
Stress echocardiography using dobutamine indication 703338002
Cardiac Decompensation indication
Cardiac Decompensation Post Cardiac Surgery indication
Organic Cardiac Disease indication
Ventricular premature beats contraindication 17338001
Myocardial infarction contraindication 22298006 DOID:5844
Hypovolemia contraindication 28560003
Hypertensive disorder contraindication 38341003 DOID:10763
Hypokalemia contraindication 43339004
Atrial fibrillation contraindication 49436004 DOID:0060224
Aortic valve stenosis contraindication 60573004 DOID:1712
Idiopathic hypertrophic subaortic stenosis contraindication 360465008




๐Ÿถ Veterinary Drug Use

None

๐Ÿถ Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 9.98 acidic
pKa2 10.59 acidic
pKa3 13.49 acidic
pKa4 9.03 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Beta-1 adrenergic receptor GPCR AGONIST EC50 5.50 WOMBAT-PK CHEMBL
Beta-2 adrenergic receptor GPCR AGONIST EC50 6.20 WOMBAT-PK CHEMBL
Sigma non-opioid intracellular receptor 1 Membrane receptor Ki 5.98 DRUG MATRIX
Sodium-dependent serotonin transporter Transporter Ki 6.00 DRUG MATRIX
Sodium-dependent noradrenaline transporter Transporter Ki 6.42 DRUG MATRIX
Alpha-2B adrenergic receptor GPCR Ki 5.87 DRUG MATRIX
D(3) dopamine receptor GPCR Ki 5.77 DRUG MATRIX
Sodium-dependent dopamine transporter Transporter Ki 6.91 DRUG MATRIX
Carbonic anhydrase 2 Enzyme Ki 6.32 CHEMBL
Alpha-1D adrenergic receptor GPCR Ki 7.35 DRUG MATRIX
Carbonic anhydrase 1 Enzyme Ki 5.72 CHEMBL
Carbonic anhydrase 4 Enzyme Ki 5.05 CHEMBL
Carbonic anhydrase 9 Enzyme Ki 5.01 CHEMBL
Carbonic anhydrase 12 Enzyme Ki 5.36 CHEMBL
Epidermal growth factor receptor Kinase IC50 5.26 DRUG MATRIX
Carbonic anhydrase 5A, mitochondrial Enzyme Ki 6.14 CHEMBL
Carbonic anhydrase 5B, mitochondrial Enzyme Ki 6.05 CHEMBL
Carbonic anhydrase 7 Enzyme Ki 5.37 CHEMBL
Tyrosine-protein kinase Lck Kinase IC50 5.26 DRUG MATRIX
Tyrosine-protein kinase Fyn Kinase IC50 5.40 DRUG MATRIX
Catechol O-methyltransferase Enzyme Km 4.30 WOMBAT-PK
Carbonic anhydrase 3 Enzyme Ki 5.13 CHEMBL
Carbonic anhydrase 6 Enzyme Ki 5.02 CHEMBL
Carbonic anhydrase 14 Enzyme Ki 4.92 CHEMBL
Solute carrier family 22 member 1 Transporter IC50 5.38 CHEMBL
Carbonic anhydrase 13 Enzyme Ki 5.02 CHEMBL
Arachidonate 15-lipoxygenase Enzyme IC50 6.22 DRUG MATRIX
Alpha-1B adrenergic receptor GPCR Ki 6.73 DRUG MATRIX
Membrane-associated progesterone receptor component 1 Membrane receptor Ki 5.80 DRUG MATRIX
Alpha-1A adrenergic receptor GPCR IC50 6.96 CHEMBL
Carbonic anhydrase 15 Enzyme Ki 6.41 CHEMBL

External reference:

IDSource
4019730 VUID
N0000147822 NUI
D00632 KEGG_DRUG
49745-95-1 SECONDARY_CAS_RN
203121 RXNORM
4017541 VANDF
4019730 VANDF
C0012963 UMLSCUI
CHEBI:4670 CHEBI
Y00 PDB_CHEM_ID
CHEMBL926 ChEMBL_ID
CHEMBL1200418 ChEMBL_ID
DB00841 DRUGBANK_ID
D004280 MESH_DESCRIPTOR_UI
36811 PUBCHEM_CID
535 IUPHAR_LIGAND_ID
3340 INN_ID
3S12J47372 UNII
2871 MMSL
4625 MMSL
d00215 MMSL
000614 NDDF
000615 NDDF
26523005 SNOMEDCT_US
387145002 SNOMEDCT_US
90118002 SNOMEDCT_US
3S12J47372 INXIGHT DRUGS

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Dobutamine HUMAN PRESCRIPTION DRUG LABEL 1 0143-9141 INJECTION, SOLUTION 12.50 mg INTRAVENOUS ANDA 20 sections
Dobutamine Hydrochloride in Dextrose HUMAN PRESCRIPTION DRUG LABEL 1 0338-1073 INJECTION 100 mg INTRAVENOUS NDA 18 sections
Dobutamine Hydrochloride in Dextrose HUMAN PRESCRIPTION DRUG LABEL 1 0338-1075 INJECTION 200 mg INTRAVENOUS NDA 18 sections
Dobutamine Hydrochloride in Dextrose HUMAN PRESCRIPTION DRUG LABEL 1 0338-1077 INJECTION 400 mg INTRAVENOUS NDA 18 sections
Dobutamine in Dextrose HUMAN PRESCRIPTION DRUG LABEL 1 0409-0025 INJECTION, SOLUTION 100 mg INTRAVENOUS NDA 18 sections
Dobutamine in Dextrose HUMAN PRESCRIPTION DRUG LABEL 1 0409-0151 INJECTION, SOLUTION 200 mg INTRAVENOUS NDA 18 sections
Dobutamine in Dextrose HUMAN PRESCRIPTION DRUG LABEL 1 0409-1100 INJECTION, SOLUTION 400 mg INTRAVENOUS NDA 18 sections
DOBUTAMINE HUMAN PRESCRIPTION DRUG LABEL 1 0409-2344 INJECTION, SOLUTION, CONCENTRATE 12.50 mg INTRAVENOUS ANDA 21 sections
DOBUTAMINE HUMAN PRESCRIPTION DRUG LABEL 1 0409-2344 INJECTION, SOLUTION, CONCENTRATE 12.50 mg INTRAVENOUS ANDA 21 sections
Dobutamine in Dextrose HUMAN PRESCRIPTION DRUG LABEL 1 0409-2346 INJECTION, SOLUTION 100 mg INTRAVENOUS NDA 18 sections
Dobutamine in Dextrose HUMAN PRESCRIPTION DRUG LABEL 1 0409-2347 INJECTION, SOLUTION 200 mg INTRAVENOUS NDA 18 sections
Dobutamine in Dextrose HUMAN PRESCRIPTION DRUG LABEL 1 0409-3724 INJECTION, SOLUTION 400 mg INTRAVENOUS NDA 18 sections
Dobutamine HUMAN PRESCRIPTION DRUG LABEL 1 14335-171 INJECTION, SOLUTION, CONCENTRATE 12.50 mg INTRAVENOUS ANDA 21 sections
Dobutamine HUMAN PRESCRIPTION DRUG LABEL 1 14335-172 INJECTION, SOLUTION, CONCENTRATE 12.50 mg INTRAVENOUS ANDA 21 sections
Dobutamine Hydrochloride in Dextrose HUMAN PRESCRIPTION DRUG LABEL 1 50090-4562 INJECTION 400 mg INTRAVENOUS NDA 18 sections
DOBUTAMINE HUMAN PRESCRIPTION DRUG LABEL 1 51662-1330 INJECTION, SOLUTION 200 mg INTRAVENOUS NDA 12 sections
DOBUTAMINE HUMAN PRESCRIPTION DRUG LABEL 1 51662-1337 INJECTION, SOLUTION, CONCENTRATE 12.50 mg INTRAVENOUS ANDA 12 sections
DOBUTAMINE HYDROCHLORIDE HUMAN PRESCRIPTION DRUG LABEL 1 51662-1566 INJECTION 100 mg INTRAVENOUS NDA 11 sections
DOBUTAMINE IN DEXTROSE HUMAN PRESCRIPTION DRUG LABEL 1 51662-1664 INJECTION, SOLUTION 100 mg INTRAVENOUS NDA 12 sections
DOBUTAMINE IN DEXTROSE HUMAN PRESCRIPTION DRUG LABEL 1 51662-1697 INJECTION, SOLUTION 100 mg INTRAVENOUS NDA 11 sections
DOBUTAMINE IN DEXTROSE HUMAN PRESCRIPTION DRUG LABEL 1 51662-1705 INJECTION, SOLUTION 200 mg INTRAVENOUS NDA 12 sections
Dobutamine HUMAN PRESCRIPTION DRUG LABEL 1 54868-5717 INJECTION, SOLUTION 12.50 mg INTRAVENOUS ANDA 11 sections
Dobutamine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 54868-5777 INJECTION, SOLUTION 400 mg INTRAVENOUS NDA 12 sections
Dobutamine HUMAN PRESCRIPTION DRUG LABEL 1 70436-203 INJECTION 250 mg INTRAVENOUS ANDA 21 sections